JPRN-UMIN000010818
Completed
未知
Evaluation of combinational effect of Aprepitant and Dxamethasone on nausea and vomiting induced by high-emetic-risk chemotherapy in patients. - PROEMEND
Osaka Medical College Hospital0 sites200 target enrollmentMay 28, 2013
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Osaka Medical College Hospital
- Enrollment
- 200
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\)Patients during pimozide administration (2\)Patients who has severe liver failure or renal failure (3\)Patients who enforced high\- or moderate\-emetic\-risk chemotherapy in the past (4\)Patients who has vomited or provoed nausea in the 24 hours prior to start of chemotherapy (5\)Patients who is considered inappropriate as a target patient by a physician\-in\-charge
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Evaluation of combinational effect of Aprepitant on nausea and vomiting induced by chemotherapy (moderate risk) in patients with Gastric Cancer or Colorectal CancerInoperable advanced/recurrence Gastric Cancer or Colorectal CancerJPRN-UMIN000008041Osaka Medical College Hospital100
Recruiting
Phase 3
Evaluation of the efficacy of Aprepitant in vomiting of children with cancerMalignant cancer.Agranulocytosis secondary to cancer chemotherapyD70.1IRCT20200204046377N1Shahid Beheshti University of Medical Sciences30
Not yet recruiting
Phase 3
A study to assess the competency of drugs between ondansetron and aprepitant in preventing patient with post surgical nausea and vomiting.Health Condition 1: K352- Acute appendicitis with generalized peritonitisHealth Condition 2: K800- Calculus of gallbladder with acutecholecystitisHealth Condition 3: N800- Endometriosis of uterusCTRI/2023/07/055093Dr. Sathya priya
Completed
Phase 3
efficacy of adding Aprepitant into antiemesis prophylactic regimen in nausea and vomiting of moderate emetogenic regimeCondition 1: nausea and vomiting. Condition 2: adverse reaction.Nausea with vomiting, unspecifiedPoisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classifiedR11.2IRCT20191103045317N1Shahid Beheshti University of Medical Sciences90
Not yet recruiting
Phase 4
Comparison between two different antiemetic regimens in patients treated with concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer : A Randomized, Double Blind, Controlled Clinical TrialCTRI/2024/06/068878Pt BD Sharma UHS Rohtak